Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer
Status:
Active, not recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of avelumab and Bacille Calmette-Guerin (BCG)
and see what effects (good and bad) that this combination treatment has on subjects with
recurrent bladder cancer.